Memantine is a pharmaceutical drug used to treat moderate and severe cases of Alzheimer's disease. Manufacturers of memantine typically produce pharmaceutical formulations with it as a standalone ingredient, although a combination formulation with donepezil is also available. Memantine suppliers market it as 5mg, 10mg, 15mg, and 20mg immediate-release as well as extended-release oral tablets, as well as in oral solution form. The patenter and earliest manufacturer of memantine intended for the treatment of Alzheimer’s disease was Merz, who first introduced it into the U.S. market under the trade name Namenda, and across other geographic markets as Ebixa. The drug is currently approved in over 80 countries globally and is a widely prescribed medication with over 4 million prescriptions registered yearly in the U.S. alone. Currently, the largest manufacturers and suppliers of memantine medications are companies Allergan, Novartis, Eisai, H. Lundbeck, Daiichi Sankyo, Ono Pharmaceutical, and Johnson & Johnson. As the number of people over the age of 65 is set to increase in the developed world, and the rate of the number of Alzheimer’s patients is projected to double by 2050, the demand for medications for the disease will increase accordingly. The primary alternatives to memantine in this market are other Alzheimer’s medications, such as donepezil, galantamine, and rivastigmine.

Some of the symptoms of Alzheimer's disease are thought to be brought on by glutamate-induced continuous activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system. Because glutamate has excitatory qualities, this overactivation is hypothesised to contribute to neurotoxicity. Memantine presumably exerts its pharmacological impact by acting as an uncompetitive NMDA receptor antagonist and blocking glutamate's ability to function on this receptor. Memantine prefers the cation channels controlled by NMDA receptors. Memantine has been shown to have antagonist effects, however it has not been demonstrated that it can stop or slow the neurodegeneration seen in people with Alzheimer's disease. Memantine is effectively absorbed after an oral dosage. In between 3 and 7 hours, the drug's peak concentrations are reached. When administered at typical therapeutic levels, memantine exhibits linear pharmacokinetics. Since food has no impact on the absorption of memantine, this medication can be taken regardless of eating. The liver only partially metabolises this medication. The hepatic CYP450 enzyme system has a minor role in this drug's metabolism.

Prices of memantine medications vary depending on whether it is an immediate-release or extended-release formulation and on whether it is a generic or trade name formulation. Costs per 56 tablets of memantine range from 7 EUR to 100 EUR. The retail prices of Memantine medications vary depending on the other active ingredients in the formulation, whether it is a generic or trade name formulation, as well as supplier and manufacturer pricing. Also the costs of Memantine vary depending on manufacturer and supplier pricing, whether it is a generic or trade name formulation, concentration of the active ingredient in the formulation. Memantine suppliers, on the whole, are in favor of patient aid initiatives. Memantine is available for sale from various Memantine vendors at multiple costs.

Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Memantine manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. PipelinePharma is the most reliable source for this medication. Finding an honest partner in our business is one of the significant challenges. To overcome this challenge and make one's life easier when looking for a direct manufacturer and supplier of Memantine, one can go to the Pipelinepharma website, which assists buyers in locating dependable manufacturers and suppliers of Memantine.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Memantine offerings can be narrowed down with filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Memantine suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Memantine. Also, each manufacturer or supplier product description contains essential information about this substance, including clinical data, stability zones, and countries in which Memantine is already registered. Manufacturers also have special delivery terms.

Suppose you are a pharmaceutical licensing company or a distributor. In that case, you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Memantine suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Memantine manufacturers for the quality of the pharmaceutical products' dossiers and protect against the risk of possible malpractices.